this can be a multi bagger stock provided the following:
1. there are 6 other compounds which are in phase 3 trials in DMD. They will have commercialised their products in the next 6-18 months. however, in my understanding, they are addressing the ambulant segment. correct me if I'm wrong. I'm not sure if any other players are in non ambulant patients.
2. 1Q1 PIP submission to EMA and the initial FDA agreement goes well
3. phase 2b is successful
4. phase 3 is successful
it's a long shot, but IMO worth the risk . the best time to enter biotechs are in stage 2b which is now.
would appreciate if anyone throws more light about the royalty agreement with Ionis?
Chart, page-2583
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |